Increasing preterm births enhances preterm birth control market

Publisher: The Insight Partners

There has been a gradual increase in the number of preterm births from last few years. As per the World Health Organization (WHO), premature birth is a leading cause of death among the child below 5 years of age. It may be due to early induction of labor or caesarean birth. Multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are others common causes of preterm births. In 2015, low birth weight and preterm birth accounted for about 17% of infant deaths. However, the number increased during 2016, with racial and ethnic differences. In the US, 1 of every 10 infants born was a preterm birth. Thus, the increasing number of preterm births is expected to promote the growth of preterm birth control market over the forecast years. However, the regulatory authorities such as Food & Drug Administration (FDA), European Medicine Agency (EMA) and others has consistently shown a tough stance towards pharmaceutical and biotechnology medicine manufacturers. The market players must comply with the requirement and guidelines of FDA and other regulatory authorities and should constantly keep a check over time to time changes made in these guidelines which is expected to hinder the preterm birth control market.

The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 Mn in 2017. The global preterm birth control market is estimated to grow with a CAGR of 4.9% from 2018-2025. The Asia Pacific per-term birth control market is expected to grow with CAGR of 5.1% to US$ 325.6 Mn in 2025 from US$ 222.4 Mn in 2017.

The major players operating in the preterm birth control market include, CooperSurgical, Inc., MEDGYN PRODUCTS, INC., Integra LifeSciences, Panpac Medical Corp., Smiths Medical, Thomas Medical, Kangge Medical, Dr. Arabin GmbH & Co. KG, AMAG Pharmaceuticals, and BEN WAY ENTERPRISES SDN BHD among others.

A number of developments have taken place within recent years in the preterm birth control market. These developments comprise of both the organic and inorganic developments contributed by the company to increase the business and revenue generation in the market. For instance, in February 2018, FDA approved Makena a progestin injection by AMAG Pharmaceuticals for the prevention of preterm birth. Launch of new products and therapeutics by the manufacturers and distributors of preterm birth control system are also expected to accelerate the growth of the market. On the other hand, growing healthcare expenditure in the emerging economies are expected to accelerate the pace of diagnostic and treatment services, and demand for technologically advanced medical devices for wide range of applications in healthcare which is expected to provide growth opportunities for the market players in these economies for the development of therapeutics and products to treat preterm births among pregnant females.